Traders should monitor the March 18 data presentation for any signals of tolerability, target engagement, or dose-dependent degradation, which could de-risk ARV-102 and support valuation. Positive signals may catalyze near-term upside, especially given recent insider buying.
Price Chart
Executive Summary
Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be presented at the AD/PD™ 2026 conference. The data will include safety, pharmacokinetic, and pharmacodynamic results from multiple doses in Parkinson’s patients, with a planned Phase 1b trial in progressive supranuclear palsy (PSP) pending regulatory feedback.
Key Facts
- ARV-102 is an oral PROTAC degrader targeting LRRK2, designed to cross the blood-brain barrier.
- Phase 1 data on safety, PK, and PD will be presented at AD/PD™ 2026 on March 18, 2026.
- Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
- No efficacy data or clinical outcomes were disclosed—only safety and pharmacological profiles.
Financial Impact
No immediate financial impact; data presentation may influence investor sentiment ahead of future trial milestones.
Risk Factors
- Phase 1 data may show limited target engagement or safety concerns, which could delay development.
- No guarantee of regulatory approval to proceed with PSP trial.
- High biotech development risk: clinical setbacks could significantly impact valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access